Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Evaluation of a single intra-articular injection of autologous protein solution for treatment of osteoarthritis in horses.

Bertone AL, Ishihara A, Zekas LJ, Wellman ML, Lewis KB, Schwarze RA, Barnaba AR, Schmall ML, Kanter PM, Genovese RL.

Am J Vet Res. 2014 Feb;75(2):141-51. doi: 10.2460/ajvr.75.2.141.

PMID:
24471750
2.

Photodynamic therapy for sarcoma pulmonary metastases: a preclinical toxicity study.

Anderson TM, Dougherty TJ, Tan D, Sumlin A, Schlossin JM, Kanter PM.

Anticancer Res. 2003 Sep-Oct;23(5A):3713-8.

PMID:
14666668
3.

Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy.

Thomas SM, Zeng Q, Dyer KF, Suscovich TJ, Kanter PM, Whalen JD, Watkins SF, Grandis JR.

Cancer Gene Ther. 2003 Jul;10(7):518-28.

PMID:
12833132
4.
5.

Lack of toxicity of EGFR antisense gene therapy.

Zeng Q, Kanter PM, Dhir R, Gooding WE, Huang L, Grandis JR.

J Exp Ther Oncol. 2002 May-Jun;2(3):174-86.

PMID:
12415634
6.

Hepatic lymphatic mapping: a pilot study for porta hepatis lymph node identification.

Kahlenberg MS, Kane JM 3rd, Kanter PM, Weber TK, Gibbs JF, Rodriguez-Bigas MA, Petrelli NJ.

Cancer Invest. 2001;19(3):256-60.

PMID:
11338882
7.

Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer.

Webb MS, Logan P, Kanter PM, St-Onge G, Gelmon K, Harasym T, Mayer LD, Bally MB.

Cancer Chemother Pharmacol. 1998;42(6):461-70.

PMID:
9788572
8.

Diabetes case management: exploring staff practice patterns.

Kanter PM, Otwell JA.

Diabetes Educ. 1996 Jul-Aug;22(4):333, 335-6, 339. No abstract available.

PMID:
8846740
9.
10.

Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs.

Kanter PM, Klaich G, Bullard GA, King JM, Pavelic ZP.

In Vivo. 1994 Nov-Dec;8(6):975-82.

PMID:
7772749
11.

Liposome encapsulated vincristine: preclinical toxicologic and pharmacologic comparison with free vincristine and empty liposomes in mice, rats and dogs.

Kanter PM, Klaich GM, Bullard GA, King JM, Bally MB, Mayer LD.

Anticancer Drugs. 1994 Oct;5(5):579-90.

PMID:
7858291
12.

Preclinical toxicologic evaluation of DENSPM (N1,N11-diethylnorspermine) in rats and dogs.

Kanter PM, Bullard GA, King JM.

Anticancer Drugs. 1994 Aug;5(4):448-56.

PMID:
7949250
13.

Induction of dog IL-1 by free and liposomal encapsulated doxorubicin.

Klaich GM, Kanter PM.

Anticancer Drugs. 1994 Jun;5(3):355-60.

PMID:
7919461
14.

Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99): comparison with doxorubicin and empty liposomes in mice and dogs.

Kanter PM, Bullard GA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP.

In Vivo. 1993 Jan-Feb;7(1):85-95.

PMID:
8504212
15.

Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs.

Kanter PM, Bullard GA, Ginsberg RA, Pilkiewicz FG, Mayer LD, Cullis PR, Pavelic ZP.

In Vivo. 1993 Jan-Feb;7(1):17-26.

PMID:
8504204
16.

Prostatic atrophy in dogs after intravenous administration of a ureido-ethylimidazoline derivative (CGP15'720A).

Kanter PM, Bullard GA, Pavelic ZP.

J Cancer Res Clin Oncol. 1991;117(6):556-60.

PMID:
1744161
17.

Preclinical toxicity study of streptozocin infused into the internal carotid artery of dogs and baboons.

Kanter PM, Bullard GA, West CR, Pavelic ZP.

J Exp Pathol. 1990;5(4):133-42.

PMID:
2151635
18.

CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties.

Schieweck K, Stanek J, Kanter PM, Schmidt-Ruppin KH, Müller M, Matter A.

Cancer Chemother Pharmacol. 1989;23(6):341-7.

PMID:
2713956
19.

Preclinical toxicity study of mitomycin C infused into the internal carotid artery of beagle dogs.

Kanter PM, Bullard GA, Pavelic ZP, West CR.

Sel Cancer Ther. 1989;5(1):23-31.

PMID:
2502826
20.

Pretreatment effects on the uptake/retention kinetics of L-dopa in Harding-Passey melanoma.

Berjian RA, Kanter PM, Bhakoo HS, Tan MH, Lawrence DD.

J Invest Dermatol. 1986 May;86(5):560-2.

21.

Therapeutic and diabetogenic potential of two newly synthesized nitrosoureido sugars.

Bernacki RJ, Wilson GL, Mossman BT, Angelino N, Kanter PM, Korytnyk W.

Cancer Res. 1985 Feb;45(2):695-702.

22.

Functional and chemical markers of PCNU activity.

Kanter PM, Schwartz HS, West CR.

Cancer Drug Deliv. 1983;1(1):11-20.

PMID:
6544115
23.

A fluorescence enhancement assay for cellular DNA damage.

Kanter PM, Schwartz HS.

Mol Pharmacol. 1982 Jul;22(1):145-51.

PMID:
6289069
24.

Tourniquet infusion versus hyperthermic perfusion.

Karakousis CP, Kanter PM, Park HC, Sharma SD, Moore R, Ewing JH.

Cancer. 1982 Mar 1;49(5):850-8.

PMID:
7059923
25.

DNA damage by anthracycline drugs in human leukemia cells.

Schwartz HS, Kanter PM.

Cancer Lett. 1981 Sep;13(4):309-13.

PMID:
6946856
26.

The soft agar clonogenicity and characterization of cells obtained from human solid tumors by mechanical and enzymatic means.

Slocum HK, Pavelic ZP, Kanter PM, Nowak NJ, Rustum YM.

Cancer Chemother Pharmacol. 1981;6(3):219-25.

PMID:
7032739
27.

DNA damage in AML cell exposed to adriamycin; correlations with clinical response to therapy.

Schwartz HS, Preisler HD, Kanter PM.

Leuk Res. 1981;5(4-5):363-6. No abstract available.

PMID:
6945466
28.

Post-repair DNA damage in X-irradiated cultured human tumour cells.

Kanter PM, Schwartz HS.

Int J Radiat Biol Relat Stud Phys Chem Med. 1980 Nov;38(5):483-93.

PMID:
6969697
29.

Tourniquet infusion chemotherapy in extremities with malignant lesions.

Karakousis CP, Rao U, Holtermann OA, Kanter PM, Holyoke ED.

Surg Gynecol Obstet. 1979 Oct;149(4):481-90.

PMID:
483125
30.
31.

A hydroxylapatite batch assay for quantitation of cellular DNA damage.

Kanter PM, Schwartz HS.

Anal Biochem. 1979 Aug;97(1):77-84. No abstract available.

PMID:
484845
32.

Chemical interactions of cardiolipin with daunorubicin and other intercalating agents.

Schwartz HS, Kanter PM.

Eur J Cancer. 1979 Jun;15(6):923-8. No abstract available.

PMID:
499278
33.
35.

Modes of regional chemotherapy.

Karakousis CP, Kanter PM, Lopez R, Moore R, Holyoke ED.

J Surg Res. 1979 Feb;26(2):134-41. No abstract available.

PMID:
423564
36.

Adriamycin-induced DNA damage in human leukemia cells.

Kanter PM, Schwartz HS.

Leuk Res. 1979;3(5):277-83. No abstract available.

PMID:
533994
37.

Comparison of regional versus systemic chemotherapy with adriamycin.

Didolkar MS, Kanter PM, Baffi RR, Schwartz HS, Lopez R.

Ann Surg. 1978 Mar;187(3):332-6.

38.

Mechanisms of selectivity of intercalating agents.

Schwartz HS, Schioppacassi G, Kanter PM.

Antibiot Chemother (1971). 1978;23:247-54. Review.

PMID:
348083

Supplemental Content

Loading ...
Support Center